Chimerix (NASDAQ:CMRX) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Chimerix (NASDAQ:CMRX - Get Free Report) in a report released on Wednesday. The firm set a "hold" rating on the biopharmaceutical company's stock.

CMRX has been the subject of a number of other reports. HC Wainwright reaffirmed a "neutral" rating and set a $8.55 price objective (down from $11.00) on shares of Chimerix in a report on Wednesday, March 5th. Wedbush reaffirmed a "neutral" rating and set a $8.55 target price (up from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Jefferies Financial Group reiterated a "hold" rating and issued a $8.50 price target (down previously from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Chimerix Stock Down 0.1 %

Shares of Chimerix stock traded down $0.01 on Wednesday, reaching $8.54. The company's stock had a trading volume of 755,354 shares, compared to its average volume of 2,227,229. Chimerix has a 52 week low of $0.75 and a 52 week high of $8.55. The company has a market capitalization of $801.09 million, a price-to-earnings ratio of -9.09 and a beta of -0.17. The firm's fifty day simple moving average is $7.31 and its two-hundred day simple moving average is $3.92.

Chimerix (NASDAQ:CMRX - Get Free Report) last posted its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.01. The firm had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.31 million. As a group, research analysts predict that Chimerix will post -0.99 EPS for the current year.

Insider Transactions at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now directly owns 609,603 shares of the company's stock, valued at $2,755,405.56. The trade was a 1.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders sold 20,760 shares of company stock worth $91,175. 13.10% of the stock is currently owned by company insiders.

Institutional Trading of Chimerix

A number of institutional investors have recently modified their holdings of CMRX. Stoneridge Investment Partners LLC increased its stake in Chimerix by 22.5% during the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company's stock valued at $154,000 after purchasing an additional 8,134 shares in the last quarter. Bender Robert & Associates acquired a new position in shares of Chimerix in the 4th quarter valued at $37,000. Susquehanna Fundamental Investments LLC purchased a new position in Chimerix in the 4th quarter worth $59,000. Jane Street Group LLC purchased a new position in Chimerix in the 4th quarter worth $62,000. Finally, Diadema Partners LP acquired a new stake in Chimerix during the 4th quarter worth about $101,000. 45.42% of the stock is currently owned by institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.